Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042989176> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2042989176 endingPage "S255" @default.
- W2042989176 startingPage "S255" @default.
- W2042989176 abstract "Our previous work showed that the major histocompatibility complex class II–related protein CD74 is overexpressed from the very early stages of chronic lymphocytic leukemia (CLL). Activation of CD74 with its ligand MIF leads to survival signals in all stages. 1 Binsky et al. Proc Natl Acad Sci U S A. 2007; 104: 13408 Crossref PubMed Scopus (146) Google Scholar Furthermore, it leads to increased VLA-4 expression, with resultant homing to the bone marrow in advanced stages of the disease. We also showed that blocking CD74 with the humanized monoclonal antibody milatuzumab leads to increased apoptosis and decreased migration to the bone marrow. 2 Binsky et al. J Immunol. 2010; 184: 4761 Crossref PubMed Scopus (44) Google Scholar We therefore decided to translate our results to a clinical trial using milatuzumab. So far, 6 patients with advanced refractory CLL have been recruited. Three of the 6 patients showed significant improvement in cytopenia, with no need for blood transfusions in 2 patients who were transfusion-dependent before enrolment. Five of 6 patients had significant improvement in B symptoms and functional level. No patient died or had significant treatment-related toxicity during the study period. Patient samples showed a decrease in bcl-2 , mcl-1 and VLA-4 mirroring those that we observed in the xenograft mouse model. Our results thus far, combined with data from other studies of milatuzumab in the United States, suggest that this agent is safe and improves quality of life and functional ability of among frail elderly patients with advanced-stage CLL. The findings also suggests that milatuzumab should be given continuously; in most patients, the effects decreased after a short period of discontinuation of therapy, in terms of both in clinical and laboratory variables. One patient received milatuzumab for more than 1 year with no significant adverse effects." @default.
- W2042989176 created "2016-06-24" @default.
- W2042989176 creator A5004066605 @default.
- W2042989176 creator A5055705705 @default.
- W2042989176 date "2011-10-01" @default.
- W2042989176 modified "2023-10-09" @default.
- W2042989176 title "5.18 Milatuzumab as a Single Agent in Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase 1–2 Study and Future Plans" @default.
- W2042989176 cites W2158508282 @default.
- W2042989176 cites W2169087490 @default.
- W2042989176 doi "https://doi.org/10.1016/j.clml.2011.09.172" @default.
- W2042989176 hasPublicationYear "2011" @default.
- W2042989176 type Work @default.
- W2042989176 sameAs 2042989176 @default.
- W2042989176 citedByCount "1" @default.
- W2042989176 countsByYear W20429891762014 @default.
- W2042989176 crossrefType "journal-article" @default.
- W2042989176 hasAuthorship W2042989176A5004066605 @default.
- W2042989176 hasAuthorship W2042989176A5055705705 @default.
- W2042989176 hasConcept C126322002 @default.
- W2042989176 hasConcept C143998085 @default.
- W2042989176 hasConcept C203014093 @default.
- W2042989176 hasConcept C2776063141 @default.
- W2042989176 hasConcept C2776364478 @default.
- W2042989176 hasConcept C2777938653 @default.
- W2042989176 hasConcept C2778461978 @default.
- W2042989176 hasConcept C2779338263 @default.
- W2042989176 hasConcept C2779878957 @default.
- W2042989176 hasConcept C2780007613 @default.
- W2042989176 hasConcept C2780366003 @default.
- W2042989176 hasConcept C2780653079 @default.
- W2042989176 hasConcept C71924100 @default.
- W2042989176 hasConceptScore W2042989176C126322002 @default.
- W2042989176 hasConceptScore W2042989176C143998085 @default.
- W2042989176 hasConceptScore W2042989176C203014093 @default.
- W2042989176 hasConceptScore W2042989176C2776063141 @default.
- W2042989176 hasConceptScore W2042989176C2776364478 @default.
- W2042989176 hasConceptScore W2042989176C2777938653 @default.
- W2042989176 hasConceptScore W2042989176C2778461978 @default.
- W2042989176 hasConceptScore W2042989176C2779338263 @default.
- W2042989176 hasConceptScore W2042989176C2779878957 @default.
- W2042989176 hasConceptScore W2042989176C2780007613 @default.
- W2042989176 hasConceptScore W2042989176C2780366003 @default.
- W2042989176 hasConceptScore W2042989176C2780653079 @default.
- W2042989176 hasConceptScore W2042989176C71924100 @default.
- W2042989176 hasLocation W20429891761 @default.
- W2042989176 hasOpenAccess W2042989176 @default.
- W2042989176 hasPrimaryLocation W20429891761 @default.
- W2042989176 hasRelatedWork W2325810813 @default.
- W2042989176 hasRelatedWork W2327483371 @default.
- W2042989176 hasRelatedWork W2468955395 @default.
- W2042989176 hasRelatedWork W2621832513 @default.
- W2042989176 hasRelatedWork W2791197850 @default.
- W2042989176 hasRelatedWork W2962711446 @default.
- W2042989176 hasRelatedWork W2979876413 @default.
- W2042989176 hasRelatedWork W4235050301 @default.
- W2042989176 hasRelatedWork W4289340451 @default.
- W2042989176 hasRelatedWork W4308636516 @default.
- W2042989176 hasVolume "11" @default.
- W2042989176 isParatext "false" @default.
- W2042989176 isRetracted "false" @default.
- W2042989176 magId "2042989176" @default.
- W2042989176 workType "article" @default.